COVID-19 and readjusting clinical trials

Aug 24, 2020

Many trials often deal with vulnerable populations who are most at risk from exposure to COVID-19. COVID-19 has affected the ability to conduct trials in safe and effective ways. Thousands of trials have been suspended or stopped because of the difficulties in continuing under lockdown conditions, even as those restrictions have begun to ease in parts of the world. The Lancet


Other news

Cookies help us deliver our services. By using our services, you agree to our use of cookies. What are cookies?